Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Genitourinary 2Dermatologic 2Breast 2Sarcoma 1Lymphoid 1

Conditions

Melanoma 2Lymphatic Metastasis 1

Interventions

pembrolizumab 157Nivolumab 132Ipilimumab 77Cyclophosphamide 46Specimen Handling 44Magnetic Resonance Spectroscopy 39cemiplimab 35Biopsy 31fludarabine 28trametinib 24relatlimab 24binimetinib 23Interleukin-2 21fludarabine phosphate 20dabrafenib 20atezolizumab 20Radiotherapy 20Opdualag 19Radiosurgery 18CTLA-4 Antigen 18encorafenib 17aldesleukin 17Blood Specimen Collection 17avelumab 14Immunoglobulin G 14Disulfides 13lenvatinib 11Bevacizumab 11lifileucel 10Paclitaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
alovudine × Dermatologic × 1 year × Clear all
NCT04221438 2026-05-29

Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement

Eastern Cooperative Oncology Group

Phase 2 Terminated
3 enrolled 11 charts
Dermatologic

Lymphatic Metastasis, Melanoma

NCT03356470 2026-01-28

Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic Melanoma

University of Wisconsin, Madison

Completed
5 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡